Overview
Publication
J AIDS Clin Res. 2015 May 23; 6(461):NA.
PubMed ID: 26587311
Title
Safety and immunogenicity of a recombinant adenovirus serotype 35-vectored HIV-1 vaccine in adenovirus serotype 5 seronegative and seropositive individuals
Authors
Fuchs JD, Bart PA, Frahm N, Morgan C, Gilbert P, Kochar N, DeRosa S, Tomaras G, Wagner T, Baden L, Koblin B, Rouphael N, Kalams S, Keefer M, Goepfert P, Sobieszczyk M, Mayer K, Swann E, Liao H-X, Haynes B, Graham B, and McElrath MJ for the NIAID HIV Vaccine Trials Network
Abstract
Recombinant adenovirus serotype 5 (rAd5)-vectored HIV-1 vaccines have not prevented HIV-1 infection or disease and pre-existing Ad5 neutralizing antibodies may limit the clinical utility of Ad5 vectors globally. Using a rare Ad serotype vector, such as Ad35, may circumvent these issues, but there are few data on the safety and immunogenicity of rAd35 directly compared to rAd5 following human vaccination.
With the publicly available data in the CAVD DataSpace we can Learn about studies, products, assays, antibodies, and publications, Find subjects with common characteristics, Plot assay results across studies and years of research, and Compare monoclonal antibodies and their neutralization curves. Data are also accessible via DataSpaceR, our R API.
Sign in to see full information about this publication and to download study data when available.